Participated · Series A · Apr 2026

Collov develops visual intelligence technology that combines diffusion models, spatial reasoning, and multi-step agentic systems to understand scenes and generate actionable outputs. Its consumer-facing applications, Collov AI and CozyAI, are used by more than 1 million users and over 300 companies and serve as product and data feedback loops to improve model performance. The company reported that its visual AI model has driven a significant increase in revenue and has been integrated into on-device systems from Qualcomm. Collov positions its technology as foundational infrastructure for next-generation AI devices such as wearables and real-time interactive systems. The founding team includes researchers and engineers from Stanford, UC Berkeley, and Yale who have contributed to multimodal AI and large-scale recommendation systems. Future plans emphasized in the article include expanding research through the new lab and accelerating adoption of camera-driven visual interfaces.

Participated · Seed · Jan 2026

Fortitude Biomedicines is a private biotechnology company pioneering next-generation biologics that combine precise immune-cell targeting with molecular glue payloads to create more effective antibody-drug conjugates. Its proprietary GLUE-DACTM discovery engine, originating from research at Baylor College of Medicine, integrates ADC precision with targeted protein degradation to widen therapeutic windows, overcome resistance, and unlock new drug targets. The company’s lead immune-cell-targeting biologic is being advanced through IND-enabling studies, funded by its recently secured seed capital. Beyond this flagship candidate, Fortitude is building a broader pipeline aimed at oncology and autoimmune indications using the GLUE-DACTM platform. Headquartered in Waltham, Massachusetts, Fortitude was co-founded by serial entrepreneur Jesse Chen, Ph.D., and Baylor College of Medicine professor Jin Wang, Ph.D.; Chen now serves as president and CEO. The business is still pre-revenue and focused on preclinical research, with future milestones centered on submitting its first IND and expanding its ADC portfolio.

Participated · Series A · Dec 2025

Deep Principle is an MIT-rooted AI-for-Science company whose founding team returned to China in 2024 to commercialise advanced, generative-AI tooling for chemistry and materials. The firm has published cover-story research on its diffusion models (OA-ReactDiff, React-OT) and LLM workflows (LLM-EO) in journals such as Nature Computational Science, Nature Machine Intelligence, Advanced Science and JACS. These models underpin the ReactiveAI platform, which was recently upgraded into Agent Mira™—an intelligent agent that can, via natural-language prompts, design molecules, predict reactions and optimise formulations by orchestrating six proprietary algorithmic modules. Deep Principle is also building an L4 high-throughput autonomous lab, AI Materials Factory™, to close the loop from in-silico prediction to physical validation under its ECML (Experiment-Compute-Machine Learning) framework. Commercial traction includes more than RMB 10 million in signed orders with partners such as Sunsea Innovation (supramolecular materials) and L'Oréal (personal care), along with ongoing collaboration with XtalPi in chemicals. Proceeds from the latest financing will accelerate Agent Mira’s R&D, complete the AI Materials Factory and deepen engagements with domestic and global customers.

Participated · Seed · Aug 2024

Kano Therapeutics is pioneering single-stranded DNA (ssDNA) as a safe, efficient and flexible biomolecule for gene insertions, using bioreactor-based production to manufacture long, circular ssDNA repair templates. Its platform connects manufacturing, application and computational tools to deliver kilobase ssDNA at roughly 10x lower cost and greatly increased scale, aiming to enable low-toxicity, high-efficiency gene constructs inaccessible to current methods. Kano positions ssDNA as combining dsDNA stability with RNA-like flexibility to replace whole genes while reducing immune activation and safety concerns associated with viral vectors and dsDNA donors. The company is founder-led and was spun out of the Bathe BioNanoLab at MIT’s Laboratory for Nucleic Acid Nanotechnology. Kano will use the financing to develop GLP standards, design a process for clinical-grade production of kilobase ssDNA, advance internal and collaborative programs, begin internal ex vivo pipeline development, expand therapeutic collaborations into pre-clinical programs, and scale production capacity. Its work targets gene and cell therapies for genetic disorders, cancers and other high unmet-need conditions. Kano Therapeutics is a biotech startup spun out of Professor Mark Bathe’s BioNano Lab at MIT focused on therapeutic replacement genes. The company is building replacement-gene therapeutics and is actively piloting products with multiple public pharma companies. Kano aims to enable drug programs in cancer immunotherapies and gene therapies for monogenetic disorders. Co-founder and CEO Floris Engelhardt, PhD, was a postdoctoral researcher in the BioNano Lab and holds a doctorate in biophysics from the Technical University of Munich. In 2021 Engelhardt received a two-year founder fellowship from Activate Global to support company building. In May 2022 Kano closed a Pre-Seed round led by Boston-based fund The Engine with participation from German fund Amino Collective.

Participated · Series A · Apr 2024

dappOS is an intent execution network that turns value-specific intents into on-chain outcomes. It creates a two-sided marketplace: on the supply side, service providers stake collateral and opt into running execution services; on the demand side, developers find solutions to fulfill users’ intents. The platform matches intents with execution services to produce on-chain results for chains and dApps. The company plans to use the Series A proceeds to expand operations and accelerate development efforts. dappOS raised $15.3M in a Series A at a $300M valuation and previously secured seed investment from Binance Labs and Sequoia China in July 2023. The company is based in Singapore and was selected for the Binance Incubation Program Season 5 in December 2022.